TY - JOUR
T1 - Association of blood pressure variability with short- and long-term cognitive outcomes in patients with critical illness
AU - Garbajs, Nika Zorko
AU - Singh, Tarun D.
AU - Valencia Morales, Diana J.
AU - Herasevich, Vitaly
AU - Warner, David O.
AU - Martin, David P.
AU - Knopman, David S.
AU - Petersen, Ronald C.
AU - Hanson, Andrew C.
AU - Jennissen, Andrew J.
AU - Schroeder, Darrell R.
AU - Weingarten, Toby N.
AU - Gajic, Ognjen
AU - Rabinstein, Alejandro A.
AU - Sprung, Juraj
N1 - Funding Information:
Dr. Knopman served on a Data Safety Monitoring Board for the DIAN study. He serves on a data safety monitoring board for a tau therapeutic for Biogen but receives no personal compensation. He is an investigator in clinical trials sponsored by Biogen , Lilly Pharmaceuticals and the University of Southern California . He serves as a consultant for Samus Therapeutics, Third Rock and Alzeca Biosciences but receives no personal compensation. He receives research support from the NIH . Dr. Petersen is a consultant for Biogen, Inc., Roche, Inc., Merck, Inc., Genentech Inc., Eisai, Inc.; has given educational lectures for GE Healthcare , receives publishing royalties from Mild Cognitive Impairment ( Oxford University Press , 2003), UpToDate, and receives research support from the NIH/NIA . Other authors have nothing to disclose.
Funding Information:
This study was supported by the Mayo Foundation for Medical Education and Research, and the Mayo Anesthesiology Small Grant Program (FP00119684). Support is provided by the Rochester Epidemiology Project (R01 AG034676) and the Mayo Clinic Center for Clinical and Translational Science (CTSA), grant number UL1 TR000135 from the National Center for Advancing Translational Sciences (NCATS).Dr. Knopman served on a Data Safety Monitoring Board for the DIAN study. He serves on a data safety monitoring board for a tau therapeutic for Biogen but receives no personal compensation. He is an investigator in clinical trials sponsored by Biogen, Lilly Pharmaceuticals and the University of Southern California. He serves as a consultant for Samus Therapeutics, Third Rock and Alzeca Biosciences but receives no personal compensation. He receives research support from the NIH. Dr. Petersen is a consultant for Biogen, Inc., Roche, Inc., Merck, Inc., Genentech Inc., Eisai, Inc.; has given educational lectures for GE Healthcare, receives publishing royalties from Mild Cognitive Impairment (Oxford University Press, 2003), UpToDate, and receives research support from the NIH/NIA. Other authors have nothing to disclose.
Funding Information:
This study was supported by the Mayo Foundation for Medical Education and Research, and the Mayo Anesthesiology Small Grant Program ( FP00119684 ). Support is provided by the Rochester Epidemiology Project ( R01 AG034676 ) and the Mayo Clinic Center for Clinical and Translational Science (CTSA), grant number UL1 TR000135 from the National Center for Advancing Translational Sciences (NCATS).
Publisher Copyright:
© 2022 Elsevier Inc.
PY - 2022/10
Y1 - 2022/10
N2 - Background: Blood pressure variability (BPV), a modifiable risk factor, can compromise cerebral perfusion in critically ill patients. We studied the association between BPV in the intensive care unit (ICU) and short- and long-term cognitive outcomes. Methods: All patients were ≥50 years old. The short-term cognitive end points were delirium and depressed alertness without delirium. The long-term outcome was change in the slope of longitudinal cognitive scores. Primary BPV measure was average real variability (ARV) of systolic blood pressure. Associations were assessed with multivariable multinominal logistic regression and linear mixed effects models. Results: Of 794 patients (1130 admissions) 185 developed delirium and 274 developed depressed alertness. There was a dose-response association of 24-h systolic ARV with delirium (adjusted OR, 95% CI 2.15 per 5 mm Hg increase, 1.31–3.06, P < 0.017) and with depressed alertness (OR 1.89, 95% CI 1.18–3.03, P < 0.008). For 371 patients with available longitudinal cognitive scores, the decline in cognitive trajectory was accelerated after discharge (annual change OR −0.097, 95% CI −0.122 to −0.073). This acceleration increased with delirium (additional decline −0.132 [−0.233 to 0.030], P = 0.011). We found no significant association between BPV and post-ICU cognitive trajectory. Conclusions: BPV was associated with increased likelihood of delirium in the ICU. Delirium, but not BPV, was associated with long-term cognitive decline.
AB - Background: Blood pressure variability (BPV), a modifiable risk factor, can compromise cerebral perfusion in critically ill patients. We studied the association between BPV in the intensive care unit (ICU) and short- and long-term cognitive outcomes. Methods: All patients were ≥50 years old. The short-term cognitive end points were delirium and depressed alertness without delirium. The long-term outcome was change in the slope of longitudinal cognitive scores. Primary BPV measure was average real variability (ARV) of systolic blood pressure. Associations were assessed with multivariable multinominal logistic regression and linear mixed effects models. Results: Of 794 patients (1130 admissions) 185 developed delirium and 274 developed depressed alertness. There was a dose-response association of 24-h systolic ARV with delirium (adjusted OR, 95% CI 2.15 per 5 mm Hg increase, 1.31–3.06, P < 0.017) and with depressed alertness (OR 1.89, 95% CI 1.18–3.03, P < 0.008). For 371 patients with available longitudinal cognitive scores, the decline in cognitive trajectory was accelerated after discharge (annual change OR −0.097, 95% CI −0.122 to −0.073). This acceleration increased with delirium (additional decline −0.132 [−0.233 to 0.030], P = 0.011). We found no significant association between BPV and post-ICU cognitive trajectory. Conclusions: BPV was associated with increased likelihood of delirium in the ICU. Delirium, but not BPV, was associated with long-term cognitive decline.
KW - Acute encephalopathy
KW - Blood pressure variability
KW - Cognitive decline
KW - Critical illness
UR - http://www.scopus.com/inward/record.url?scp=85134435599&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85134435599&partnerID=8YFLogxK
U2 - 10.1016/j.jcrc.2022.154107
DO - 10.1016/j.jcrc.2022.154107
M3 - Article
C2 - 35803011
AN - SCOPUS:85134435599
SN - 0883-9441
VL - 71
JO - Journal of Critical Care
JF - Journal of Critical Care
M1 - 154107
ER -